Vericel Co. (NASDAQ:VCEL) Receives $55.75 Average Price Target from Analysts

Shares of Vericel Co. (NASDAQ:VCEL) have been given an average rating of “Buy” by the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $55.75.

A number of equities research analysts recently issued reports on the stock. TD Cowen upped their price objective on shares of Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th. Canaccord Genuity Group initiated coverage on Vericel in a research note on Friday, August 9th. They set a “buy” rating and a $57.00 price target for the company. Stephens raised their price objective on Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Truist Financial boosted their target price on Vericel from $56.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Finally, Canaccord Genuity Group began coverage on Vericel in a report on Friday, August 9th. They set a “buy” rating and a $57.00 price target on the stock.

Vericel Price Performance

VCEL opened at $43.70 on Thursday. The company has a market capitalization of $2.12 billion, a PE ratio of -4,370.00 and a beta of 1.67. The business has a 50-day moving average of $48.44 and a 200-day moving average of $47.44. Vericel has a fifty-two week low of $30.18 and a fifty-two week high of $54.10.

Vericel (NASDAQ:VCEL) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). Vericel had a net margin of 0.37% and a return on equity of 0.35%. The firm had revenue of $52.70 million during the quarter, compared to analysts’ expectations of $52.59 million. During the same period in the previous year, the company earned ($0.11) earnings per share. The company’s revenue was up 14.8% compared to the same quarter last year. On average, equities research analysts expect that Vericel will post 0.1 earnings per share for the current fiscal year.

Insider Transactions at Vericel

In other news, insider Sean C. Flynn sold 6,772 shares of the firm’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $45.02, for a total value of $304,875.44. Following the sale, the insider now owns 487 shares in the company, valued at $21,924.74. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Sean C. Flynn sold 6,772 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $45.02, for a total value of $304,875.44. Following the completion of the sale, the insider now owns 487 shares in the company, valued at $21,924.74. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Dominick Colangelo sold 17,500 shares of Vericel stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $51.40, for a total value of $899,500.00. Following the sale, the chief executive officer now directly owns 220,937 shares in the company, valued at $11,356,161.80. The disclosure for this sale can be found here. Insiders sold a total of 46,291 shares of company stock worth $2,329,169 over the last three months. 5.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Nisa Investment Advisors LLC boosted its stake in Vericel by 9.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock worth $114,000 after buying an additional 220 shares in the last quarter. MCF Advisors LLC lifted its holdings in shares of Vericel by 86.1% during the 1st quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 223 shares during the period. Swiss National Bank boosted its position in shares of Vericel by 0.4% during the 1st quarter. Swiss National Bank now owns 89,500 shares of the biotechnology company’s stock valued at $4,656,000 after acquiring an additional 400 shares in the last quarter. PFG Investments LLC increased its stake in Vericel by 6.2% in the second quarter. PFG Investments LLC now owns 6,850 shares of the biotechnology company’s stock valued at $314,000 after acquiring an additional 400 shares during the period. Finally, Arizona State Retirement System raised its position in Vericel by 3.3% in the second quarter. Arizona State Retirement System now owns 12,866 shares of the biotechnology company’s stock worth $590,000 after purchasing an additional 406 shares in the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.